Komodo Health: A Qualified Entity
Delve into Komodo’s Qualified Entity reports, which examine national provider performance across the clinical measures that are critical for improving health outcomes.
Komodo Health believes that smarter, more innovative use of data and analytics is essential for reducing disease burden. Core to our mission is the tenet that the insights generated using our solutions make an impact for the greater good, ultimately helping to identify and close gaps in care.
Komodo has the unique ability to generate insights from patient-level claims data reflecting all Medicare beneficiaries alongside broader commercial data in Komodo’s Healthcare Map®. These analyses of provider performance metrics shed light on health outcomes and clinical trends in the U.S.
Explore Komodo's QE Reports
Use of Imaging Studies for Low Back Pain (LBP) (Measurement Year 2021)
Komodo Health has adopted a new measure that looks at the use of diagnostic imaging following a low back pain diagnosis. Analyses were conducted to measure rate differences by age, sex, race, ethnicity, and insurance group.
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (Measurement Year 2020)
Reported rates continue to suggest that there remain a substantial number of patients who are at-risk for hyperglycemia and diabetes mellitus by virtue of their exposure to atypical antipsychotics, but are not being screened. The data suggest that the COVID pandemic may have created additional risk related to delay in identification or intervention for hyperglycemia or medication-induced diabetes.
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (Measurement Year 2019)
A new report by Komodo Health found overall diabetes screening rates have fluctuated for several years, suggesting that there may be a substantial number of patients who are at-risk for hyperglycemia and diabetes mellitus, by virtue of their exposure to atypical antipsychotics, who are not being screened.
Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (Measurement Year 2019)
A new analysis found that although three-year DMARD dispense rates have increased overall, rates for Medicaid Managed Care and the Medicare-Medicaid Dual groups trended downward (as compared to 2018).
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (Measurement Year 2018)
Komodo Health conducted an analysis on whether patients with schizophrenia or bipolar disorder who were prescribed an antipsychotic medication had a diabetes screening during the measurement year.
Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (Measurement Year 2018)
Komodo Health conducted an analysis of patients who were diagnosed with rheumatoid arthritis and received at least one Disease Modifying Anti-Rheumatic Drug (DMARD) during the measurement year.
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (Measurement Year 2017)
According to an analysis conducted by Komodo Health, many patients who are prescribed medications that can disrupt normal serum glucose control do not receive annual screening for diabetes and other metabolic disorders.
“Despite an onslaught of data in healthcare today, there is a surprising absence of insights that healthcare stakeholders can act on with confidence. We believe that healthcare needs a source of ground truth to close gaps in care delivery. Our ability to capture a more complete view of patient journeys enables Komodo Health to address disease burden through a richer understanding of public health.”
Arif Nathoo, MD
CEO, Komodo Health
Komodo Health has been certified under the CMS Qualified Entity (QE) Program since 2017. As a QE, Komodo Health is entrusted with claims data under Medicare Parts A, B, and D for use in evaluating the performance of healthcare providers in the U.S. health system. During its tenure in the CMS QE Program, Komodo has been systematically evaluating health system performance, access to care, and effectiveness in healthcare delivery across the entire payer landscape.
Komodo’s Healthcare Map® captures insights into 330 million patient journeys for a comprehensive view of de-identified patient encounters. Insights from the Healthcare Map, in combination with QE data, enable the company to model the epidemiology of disease and help health system stakeholders direct resources where they are needed most.
Notices and Disclaimers from NCQA
NCQA Copyright Notice and Disclaimer
The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA’s Measure Certification Program. Reprinted with permission by NCQA. © 2025 NCQA, all rights reserved.
Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.
CPT Copyright 2025 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
The CDC Race and Ethnicity code system was developed by the U.S. Centers for Disease Control and Prevention (CDC). NCQA’s use of the code system does not imply endorsement by the CDC of NCQA, or its products or services. The code system is otherwise available on the CDC website for no charge.
Certain NullFlavor codes are owned and copyrighted by Health Level Seven International (HL7); 2025.
The American Hospital Association holds a copyright to the Uniform Billing Codes (“UB”) contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. All uses of the UB Codes may require a license from the AHA. Specifically, anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact [email protected].
Health Care Provider Taxonomy Code Set codes copyright 2025 AMA. The codes are published in cooperation with the National Uniform Claim Committee (NUCC) by the AMAS. Applicable FARS/DFARS restrictions apply. The American Dental Association (“ADA”) holds a copyright to the Current Dental Terminology (“CDT”) codes contained in certain measure specifications. The CDT codes in the HEDIS specifications are included with the permission of the ADA. All uses of the CDT codes require a license from the ADA. No alteration, amendments, or modifications of the CDT or any portion thereof is allowed. Resale, transmission, or distribution of copies of the CDT or other portions of the CDT is also not allowed. To inquire about licensing, contact [email protected]. RadLex copyright 2014, The Radiological Society of North America (RSNA), all rights reserved. Licensed under RadLex License Version 2.0. You may obtain a copy of the license at: http://www.rsna.org/radlexdownloads/ This work is distributed under the above noted license on an “AS IS” basis, WITHOUT WARRANTIES OF ANY KIND, either express or implied. Please see the license for complete terms and conditions.
NCQA Measure Adjustment and Certification Notices
Unadjusted Uncertified Measures: The logic used to produce these HEDIS® measure results has not been certified by NCQA. Such results are not an indication of measure validity. A calculated measure result (a “rate”) from a HEDIS measure that has not been certified via NCQA’s Measure Certification Program, and is based on unadjusted HEDIS specifications, may not be called a “Health Plan HEDIS rate” until it is audited and designated reportable by an NCQA-Certified HEDIS Compliance Auditor. Until such time, such measure rates shall be designated or referred to as “Uncertified, Unaudited Health Plan HEDIS Rates.”
Adjusted Uncertified Measures: The logic used to produce these HEDIS® measure results has not been certified by NCQA. Such results are not an indication of measure validity. A calculated measure result (a “rate”) from a HEDIS measure that has not been certified via NCQA’s Measure Certification Program, and is based on adjusted HEDIS specifications, may not be called an “Adjusted HEDIS rate” until it is audited and designated reportable by an NCQA-Certified HEDIS Compliance Auditor. Until such time, such measure rates shall be designated or referred to as “Uncertified, Adjusted, Unaudited HEDIS Rates.”